iBiopsy®: promising results on a preliminary study to evaluate the risk of tumor recurrence in patients with primary liver cancer
Median Technologies announces today the results of a preliminary retrospective study on the evaluation of the risk of recurrence for patients with primary liver cancer (HCC – hepatocellular carcinoma) based on a non-invasive biomarker.
Read more